PGPEP1: A Drug Target / Disease Biomarker (G54858)

Target Name: PGPEP1

NCBI ID: G54858

PGPEP1

PGPEP1: A Drug Target / Disease Biomarker

PGPEP1, also known as interleukin-18 (IL-18), is a protein that is expressed in various tissues throughout the body, including the immune system, skin, and tissues. It is a key player in the regulation of inflammation and immune responses, and has been implicated in a number of diseases, including cancer, autoimmune disorders, and obesity.

One of the key functions of PGPEP1 is its role in the regulation of inflammation. When the body is exposed to an infection or injury, PGPEP1 helps to coordinate the immune response by promoting the recruitment of immune cells to the site of injury or infection. It also plays a key role in the production of pro-inflammatory cytokines, which help to recruit additional immune cells to the site of inflammation and contribute to the development of tissue damage and inflammation.

In addition to its role in inflammation, PGPEP1 is also involved in the regulation of cell signaling and metabolism. It has been shown to play a role in the regulation of cell proliferation, differentiation, and survival, and has been implicated in a number of diseases, including cancer.

One of the ways that PGPEP1 is involved in cancer is its role in the regulation of angiogenesis, the process by which new blood vessels are formed in tumors. PGPEP1 has been shown to promote the growth and survival of cancer cells, and has been linked to the development of a number of cancers, including breast, ovarian, and prostate cancers.

Another way that PGPEP1 is involved in cancer is its role in the regulation of immune surveillance. PGPEP1 has been shown to dampen the immune response, which is important for the survival of cancer cells. This is because PGPEP1 helps to regulate the activity of T cells, which are a key component of the immune system and are responsible for detecting and destroying cancer cells.

In addition to its role in cancer, PGPEP1 is also involved in a number of other diseases and disorders. For example, it has been implicated in the development and progression of autoimmune disorders, such as rheumatoid arthritis and lupus. It has also been linked to a number of obesity-related diseases, including obesity and type 2 diabetes.

Despite the many promising findings about PGPEP1, more research is needed to fully understand its role in these diseases and disorders. For example, it is not yet clear exactly how PGPEP1 promotes the growth and survival of cancer cells, or how it contributes to the development and progression of autoimmune disorders. Further research is needed to fully understand the mechanisms by which PGPEP1 functions and to identify new potential drug targets or biomarkers.

In conclusion, PGPEP1 is a protein that is expressed in a variety of tissues throughout the body and plays a key role in the regulation of inflammation, cell signaling, and metabolism. It is involved in the development and progression of a number of diseases and disorders, including cancer and autoimmune disorders. Further research is needed to fully understand its role and to identify new potential drug targets or biomarkers.

Protein Name: Pyroglutamyl-peptidase I

Functions: Removes 5-oxoproline from various penultimate amino acid residues except L-proline

The "PGPEP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PGPEP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets